Contact us
Please fill out the details below and we will get back to you shortly.
Thank you!
We will be contacting you soon..
Close
We will be contacting you soon..
Oops! Something went wrong while submitting the form.
Portal Instruments has been featured in Fierce Pharma. The article titled, "Gerresheimer invests in Portal's needle-free drug delivery, teeing Takeda partner up to advance tech", showcases Gerresheimer's agreement with Portal to support the development of the needle-free drug delivery platform.
On May 9th, Fierce Pharma published an article showcasing Gerresheimer's investment into Portal Instruments. The article titled, "Gerresheimer invests in Portal's needle-free drug delivery, teeing Takeda partner up to advance tech", showcases Gerresheimer's agreement with Portal to support the development of the needle-free drug delivery platform.
Read the full article here:
March 27th, 2020 Portal’s mission is to improve the experience for patients on life-changing therapies and that mission remains in the forefront of our minds as we, like everyone else, navigate these unchartered waters with the COVID-19 pandemic.
Needles are a 150-year-old technology. The world around us is rapidly evolving but drug delivery has not made the same technological strides that other medical devices have. Portal Instruments is looking to change that with a highly innovative needle-free drug delivery injector.
Drug development is a costly, long, and uncertain endeavor. The cost of taking a drug from preclinical research through market approval is $2.6 billion according to a recent study by the Tufts Center for the Study of Drug Development.
Please fill out the details below and we will get back to you shortly.